Story perspectives

Novartis Acquires Tourmaline to Boost Cardiovascular Innovation

10/29/2025

50 6

Summary

Story summary

Novartis completed the acquisition of Tourmaline Bio, Inc. on October 28, 2025, making Tourmaline a wholly owned subsidiary.
Tourmaline's shares ceased trading on the Nasdaq.
The acquisition aims to strengthen Novartis's cardiovascular innovation by leveraging Tourmaline’s anti-IL-6 mechanism targeting inflammation linked to cardiovascular disease.
Novartis cautioned there are no guarantees about the success of Tourmaline’s clinical trials.
The tender offer concluded with approximately 92.94% of Tourmaline’s shares tendered.

1 of 1

Story summary

Novartis completed the acquisition of Tourmaline Bio, Inc. on October 28, 2025, making Tourmaline a wholly owned subsidiary.
Tourmaline's shares ceased trading on the Nasdaq.
The acquisition aims to strengthen Novartis's cardiovascular innovation by leveraging Tourmaline’s anti-IL-6 mechanism targeting inflammation linked to cardiovascular disease.
Novartis cautioned there are no guarantees about the success of Tourmaline’s clinical trials.
The tender offer concluded with approximately 92.94% of Tourmaline’s shares tendered.